Drug Profile
Research programme: galanin modulators - Synaptic Pharmaceutical
Latest Information Update: 20 Aug 2007
Price :
$50
*
At a glance
- Originator Lundbeck Research USA
- Class
- Mechanism of Action Galanin receptor agonists; Galanin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Alzheimer's disease; Diabetes mellitus; Major depressive disorder; Obesity; Pain
Most Recent Events
- 07 Aug 2003 No development reported - Preclinical for Alzheimer's disease in USA (unspecified route)
- 07 Aug 2003 No development reported - Preclinical for Depression in USA (unspecified route)
- 07 Aug 2003 No development reported - Preclinical for Diabetes mellitus in USA (unspecified route)